MA-ULTIVUE
9.3.2022 11:02:08 CET | Business Wire | Press release
Ultivue, Inc., an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Aignostics GmbH, a global leader in Artificial Intelligence (AI) powered precision diagnostics focused on pathology to assist with research, clinical trials and CDx development, announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.
The companies have already been working together since early 2021 to adapt Aignostics’ client platform to support visualization and analysis for some of Ultivue’s products and services, as well as provisioning of results and corresponding reports. The resulting co-developed platform will now be made available to joint clients. Additionally, proof of concept work conducted on the Ultivue 12-plex Immunophenotyping biomarker panel in over 1,000 clinical NSCLC cases has demonstrated encouraging results for the capacity of AI-based analysis of multiplexed images for more consistent and reproducible readouts at scale. These results will be published later this year and respective AI models made available via the platform.
The companies are now expanding their relationship under a co-marketing agreement to offer the multiplex immunofluorescence (mIF) platform to their respective biotech and pharma clients, initially for research use, with a GCP-compliant version to follow later this year. Moreover, Ultivue and Aignostics will offer AI-powered image analysis services within the platform via Aignostics “Explainable AI” approach for the consistent and precise analysis of mIF cohorts at scale, for both translational research and clinical trial research services in Ultivue’s CLIA accredited clinical research laboratory. “We are excited to extend our workflow offering to include mIF AI for highly automated image analysis by partnering with Aignostics,” says Florian Leiss, VP Digital Health at Ultivue. “Improved viewing capabilities enable us to interactively explore the interplay of mIF-labeled cell populations in the histological context of same-slide H&E.”
“We believe that development of Ultivue’s assays with our AI-powered image analysis will create insights from data at scale that are unprecedented in spatial biology today. We are excited to start offering this approach to our clients for translational science and clinical trials,” said Viktor Matyas, CEO of Aignostics.
Besides offering research and development services to its clients, Ultivue and Aignostics will also develop products for standardized analysis of certain Ultivue products, paving the way for more widespread use of these technologies in both clinical trials and clinical routine.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
About Aignostics
Aignostics, a Berlin based company with offices in the US, is a digital pathology company dedicated to novel precision diagnostics through the use of a proprietary “Explainable AI” platform in pre-clinical and translational research and clinical trials. The use of such technology is expected to be crucial to implementation of AI-powered algorithms in routine diagnostics in order to verify (explain) the model’s decision outputs. Additionally, through its close alignment to Charité and TU Berlin amongst other collaborators, only Aignostics offers the combination of data access, sample testing and pathology expertise to develop digital pathology algorithms spanning multi-modal biomarker assay detection systems such as H&E, IHC and mIF, amongst others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Launches Consumer FX: Shop From Klarna Merchants Worldwide, Regardless of Currency21.10.2026 14:47:00 CEST | Press release
Klarna Group Plc (NYSE: KLAR), the everyday finance network, today launched Consumer FX, which allows shoppers to buy from any participating Klarna merchant in the world and pay in their own currency, with no exchange fee. The price and rate are shown upfront and stay visible in the Klarna app after purchase, so there are no surprises on the statement. The new launch means any Klarna connected merchant can sell to Klarna’s 120 million consumers in 26 countries with no new integration, and no need for a local entity of foreign bank account. Klarna also handles FX disclosure, consent and compliance. Early results show merchants gain a 5% lift in conversion and 6% in sales due to the expanded reach. The launch comes as cross-border payments are growing globally. DHL reports that 70% of 2026 shoppers buy internationally, up 10% from 2025, and 45% buy across borders more than once a month.1 “Increasingly, shoppers aren’t thinking in borders,” says David Sykes, Chief Commercial Officer, Klar
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors21.10.2026 14:35:00 CEST | Press release
Collaboration to explore how AI-facilitated technology can help make patient support programs more individualized, responsive and continuously available to people living with rare tumorsCollaboration brings together clinical and pharmaceutical expertise, digital health product development, and enterprise AI servicesMerck aims to bring the model to patients with desmoid tumors and neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) Merck, a leading science and technology company, today announced a collaboration with NVIDIA Corporation (Santa Clara, California, USA), Microsoft Corporation (Redmond, Washington, USA) and Dawn Health A/S (Copenhagen, Denmark) to build an innovative model for Patient Support Programs (PSPs). The four-way collaboration brings together pharmaceutical and clinical expertise, enterprise technology, AI services and digital health product design, with the shared goal of making specialist-level support more individualized, responsive and continuously ava
Corpay Cross-Border Named the Official FX Partner of Newcastle United21.10.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into a multi-year agreement with Newcastle United to become their Official Foreign Exchange (FX) Partner. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Newcastle United’s day-to-day business operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “We’re thrilled to be named the Official FX Partner of Newcastle United, one of the Premier League’s most iconic and ambitious clubs,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership further strengthens Corpay’s position as the trusted corporate payments and currency risk management provider of choice across the Premier League. We loo
Insight Named an OpenAI Advanced Partner to Accelerate Midmarket Enterprise AI Adoption21.10.2026 14:28:00 CEST | Press release
As an OpenAI Advanced Partner, Insight will accelerate ChatGPT Enterprise, Codex, and AI adoption at scale through its Radius™ and Rapid AI offerings Insight Enterprises (NASDAQ: NSIT) today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network, reinforcing Insight's position as a provider of AI solutions for midmarket and lower-enterprise organisations seeking to accelerate AI adoption. As part of the expanded relationship, Insight will work with OpenAI to help organisations build, deploy and scale AI solutions responsibly and effectively. The expanded relationship reflects Insight's experience helping organisations successfully deploy and scale AI. “Insight has built a repeatable approach that connects technology, process transformation, and workforce adoption so clients can move from pilots to production and results faster,” said Jack Azagury, Insight President and CEO. “As an OpenAI Advanced Partner, we can help more organisations deploy AI r
Amadeus Explores Next-Generation Flight Search with NVIDIA21.10.2026 14:00:00 CEST | Press release
Amadeus and NVIDIA have been collaborating to explore how accelerated computing and travel-specific AI could support faster, more scalable and more efficient flight search. Building on this work, the companies have now signed a Memorandum of Understanding (MoU) to deepen their collaboration and accelerate further exploration. As AI assistants increasingly search on behalf of travelers, they are changing both the volume and complexity of demand placed on travel technology. Amadeus, in collaboration with NVIDIA, have already conducted initial technical assessments and benchmarking activities, on the NVIDIA Hopper and Blackwell platform, NVIDIA's accelerated computing architectures designed for AI and high-performance computing workloads, to better understand how accelerated computing could support large-scale travel shopping workloads. Through the MoU, Amadeus and NVIDIA will continue this collaboration, with aims to deliver faster, more scalable and more efficient flight search as AI-po
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom